U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT07483177) titled 'HEART: Pilot Randomized Controlled Trial' on March 16.

Brief Summary: The purpose of this study is to determine whether spironolactone reduces aortic stiffness, measured by carotid-femoral pulse wave velocity (cfPWV), compared with placebo, in patients with degenerative thoracic aortic aneurysms.

Study Start Date: May, 2026

Study Type: INTERVENTIONAL

Condition: Thoracic Aortic Aneurysm

Intervention: DRUG: Spironolactone

Subjects will receive spironolactone 25 mg once daily for the first 4 weeks, followed by an increased dose of 50 mg once daily for an additional 5 months.

DRUG: Placebo

Subjects will receive 25 mg of the pl...